KLRK1 and plasma cell myeloma: The exposure of myeloma cells to doxorubicin, melphalan, or bortezomib upregulates DNAM-1 and NKG2D ligands through initiating a DNA damage response, an ATM-dependent activation of p53, and inducing senescence, which may contribute to the therapeutic mechanism of these agents [9,35,36].